4th Quarter - Amendment

THE MCMANUS GROUP for DENDREON PHARMACEUTICALS LLC

Firm
Client
Income
$30,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 17, 2020 $30,000 Replaced
4th Quarter - Amendment (this page) Aug 6, 2020 $30,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19, the Lower Costs, More Cures Act of 2019.

Foreign entity interest: Dendreon is a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.

LobbyistCovered position, as disclosed
PAUL BRYAN CRONAN —
JOHN MCMANUS LA, Bill Thomas. Staff Director, W&M Health Subcommittee
BARRETT THORNHILL LA, Sen. Crapo and Rep. Toomey. LA and Press Secretary, Rep. Norwood.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 19 (116th), S. 2543 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.